Who are Direct-acting oral anticoagulation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral Anticoagulant, Direct-Acting.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/direct-acting-oral-anticoagulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Direct-acting oral anticoagulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Direct-acting oral anticoagulation (Direct-acting oral anticoagulation) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting oral anticoagulant (DOAC). Area: Cardiovascular.

marketed Direct-acting oral anticoagulant (DOAC) Factor IIa or Factor Xa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Direct-acting oral anticoagulation (Direct-acting oral anticoagulation) — Hospital Universitario La Fe. Direct-acting oral anticoagulants inhibit specific clotting factors (either Factor IIa or Factor Xa) to prevent thrombus formation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Direct-acting oral anticoagulation TARGET	Direct-acting oral anticoagulation	Hospital Universitario La Fe	marketed	Direct-acting oral anticoagulant (DOAC)	Factor IIa or Factor Xa
Oral Anticoagulant, Direct-Acting	Oral Anticoagulant, Direct-Acting	Assistance Publique - Hôpitaux de Paris	phase 3	Direct-acting oral anticoagulant (DOAC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting oral anticoagulant (DOAC) class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Hospital Universitario La Fe · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Direct-acting oral anticoagulation — Competitive Intelligence Brief. https://druglandscape.com/ci/direct-acting-oral-anticoagulation. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab